ARVN

Based on Arvinas, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Arvinas do?

Arvinas is a clinical-stage biopharmaceutical company developing PROTAC protein degraders — a novel class of molecules that direct the body's own cellular machinery to destroy disease-causing proteins. Its pipeline focuses primarily on cancers driven by the androgen receptor and estrogen receptor, with collaborations supporting its research.

Does ARVN pay dividends?

No, Arvinas does not pay a dividend. As a clinical-stage company with no approved products, it reinvests all capital into research and clinical development. Investors in ARVN are seeking potential capital appreciation from pipeline progress rather than income.

When does ARVN report earnings?

Arvinas reports on a quarterly cadence, standard for US-listed public companies. Because it is pre-revenue, the most watched disclosures are clinical trial updates and collaboration milestones. Check Arvinas's investor relations page for the current reporting schedule.

Is ARVN a good stock to buy?

UQS Score rates ARVN as Poor overall, driven by Weak ratings across Quality, Moat, and Growth pillars and an Elevated Valuation. That profile reflects the high uncertainty inherent in clinical-stage biotech investing. The full pillar breakdown is available to UQS Pro members.

Is ARVN overvalued?

The UQS Valuation pillar for ARVN is rated Elevated, indicating the current market price embeds meaningful optimism about future pipeline success. For a pre-revenue biotech, valuation is largely driven by probability-weighted clinical outcomes rather than current financials.

How does ARVN compare to its competitors?

Arvinas competes in the broader clinical-stage biotech space. Compared to peers like Alpha Tau Medical, Bright Minds Biosciences, and Prime Medicine, Arvinas is differentiated by its PROTAC platform and its high-profile pharma collaborations with Pfizer and Roche. Each company pursues distinct therapeutic modalities.

What is ARVN's market cap bracket?

Arvinas is classified as a small-cap stock. This reflects its pre-commercial stage — the company has not yet generated product revenue, and its market value is driven by pipeline potential and partnership agreements rather than earnings.

Who founded Arvinas?

Arvinas was founded in 2013. The company's founding is rooted in academic research on targeted protein degradation. Detailed founding history, including key individuals involved, is widely available through Arvinas's public disclosures and investor relations materials.

Is ARVN a long-term quality investment?

From a long-term quality perspective, ARVN's UQS profile currently rates as Poor, with Weak scores across Quality, Moat, and Growth. Long-term quality indicators would need to improve — particularly through clinical success and eventual commercialization — before the profile strengthens materially.

What is the main competitive advantage of Arvinas?

Arvinas's primary differentiator is its proprietary PROTAC protein degrader platform, which targets disease-causing proteins for elimination rather than mere inhibition. This approach has attracted partnerships with major pharmaceutical companies, providing both validation and non-dilutive funding to support its pipeline.

What sector does ARVN belong to?

Arvinas operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Its focus on oncology and novel protein degradation biology places it in one of the more research-intensive and risk-bearing segments of the healthcare industry.

Is ARVN a growth stock or value stock?

Based on UQS pillar labels, ARVN carries a Weak Growth rating and an Elevated Valuation rating — a combination that does not fit neatly into either category. It is best understood as a speculative clinical-stage biotech where value depends almost entirely on pipeline outcomes.

Arvinas, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Arvinas, Inc. shows steady but unspectacular growth, typical for mature companies.

Arvinas, Inc. maintains a reasonable risk profile with manageable debt levels.

Arvinas, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Arvinas, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ARVN.

The UQS (Unified Quality Score) for Arvinas, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Arvinas, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Arvinas, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.